Omeros Corporation (NASDAQ:OMER) fell 6.3% during mid-day trading on Wednesday after Wedbush lowered their price target on the stock from $56.00 to $47.00. Wedbush currently has an outperform rating on the stock. Omeros Corporation traded as low as $12.80 and last traded at $12.89, with a volume of 996,182 shares changing hands. The stock had previously closed at $13.75.

A number of other equities research analysts have also commented on the stock. Maxim Group lowered their price target on shares of Omeros Corporation from $30.00 to $19.00 and set a “buy” rating for the company in a report on Wednesday, August 10th. Cantor Fitzgerald reiterated a “buy” rating and set a $21.00 price target on shares of Omeros Corporation in a report on Monday, October 17th. Zacks Investment Research upgraded shares of Omeros Corporation from a “sell” rating to a “hold” rating in a report on Wednesday, October 19th. Needham & Company LLC lowered their price target on shares of Omeros Corporation from $28.00 to $24.00 and set a “buy” rating for the company in a report on Thursday, November 10th. Finally, FBR & Co reiterated a “buy” rating on shares of Omeros Corporation in a report on Thursday, November 10th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $33.23.

In other Omeros Corporation news, VP Marcia S. Kelbon sold 16,000 shares of the company’s stock in a transaction on Thursday, September 15th. The shares were sold at an average price of $10.91, for a total value of $174,560.00. Following the completion of the transaction, the vice president now directly owns 179,597 shares in the company, valued at approximately $1,959,403.27. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 13.60% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Investment Management LLC raised its position in shares of Omeros Corporation by 12.6% in the second quarter. BlackRock Investment Management LLC now owns 154,233 shares of the biopharmaceutical company’s stock valued at $1,623,000 after buying an additional 17,226 shares during the last quarter. BlackRock Advisors LLC raised its position in shares of Omeros Corporation by 1.0% in the second quarter. BlackRock Advisors LLC now owns 17,415 shares of the biopharmaceutical company’s stock valued at $183,000 after buying an additional 173 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Omeros Corporation by 2.3% in the second quarter. Vanguard Group Inc. now owns 1,430,125 shares of the biopharmaceutical company’s stock valued at $15,045,000 after buying an additional 32,401 shares during the last quarter. Brown Advisory Inc. raised its position in shares of Omeros Corporation by 4.0% in the second quarter. Brown Advisory Inc. now owns 543,763 shares of the biopharmaceutical company’s stock valued at $5,721,000 after buying an additional 21,133 shares during the last quarter. Finally, Nationwide Fund Advisors raised its position in shares of Omeros Corporation by 0.9% in the second quarter. Nationwide Fund Advisors now owns 67,255 shares of the biopharmaceutical company’s stock valued at $708,000 after buying an additional 631 shares during the last quarter. Institutional investors own 51.86% of the company’s stock.

The firm’s market capitalization is $568.19 million. The stock has a 50-day moving average of $9.57 and a 200 day moving average of $10.86.

Omeros Corporation (NASDAQ:OMER) last posted its earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.06. The business earned $11.30 million during the quarter, compared to analysts’ expectations of $11.64 million. During the same period last year, the business posted ($0.53) earnings per share. The company’s revenue for the quarter was up 253.1% compared to the same quarter last year. Equities research analysts anticipate that Omeros Corporation will post ($1.63) earnings per share for the current year.

Omeros Corporation Company Profile

Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.

5 Day Chart for NASDAQ:OMER

Receive News & Stock Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related stocks with our FREE daily email newsletter.